Crooke / Prestayko Introduction to Clinical Oncology

1. Auflage 2013
ISBN: 978-1-4832-6790-6
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 396 Seiten, Web PDF

9780121978020 Cancer and Chemotherapy, Volume II: Introduction to Clinical Oncology provides the basic framework for understanding antineoplastic drugs. The use of chemotherapeutics in the treatment of the most common human malignancies, including leukemias and lymphomas, is discussed. Solid tumors such as those affecting the breast and lung, head and neck, brain and spinal cord are also considered. Comprised of 17 chapters, this volume begins with an overview of leukemias and lymphomas, including their incidence, pathology, and clinical features. The discussion then turns to solid tumors such as breast and lung carcinoma; head and neck cancers; cancer of the brain and spinal cord; gastrointestinal, genitourinary, and gynecological cancers; and malignant melanoma. The next section is devoted to nutritional and infectious disease aspects of cancer and examines infections that arise in the cancer patient, particularly pneumonia and septicemia. The diagnosis of and therapy for these infections are outlined, along with granulocyte transfusion and prophylaxis of infection. The final chapter deals with nutrition in cancer patients and describes the link between cancer and malnutrition as well as the mechanisms of cancer-associated malnutrition. The advantages and methods of nutritional support for cancer patients are also highlighted. This book should be a valuable resource for oncologists.

Autoren/Hrsg.

Crooke, Stanley T.

Prestayko, Archie W.

Inhaltsverzeichnis

1;Front Cover;1
2;Introduction to Clinical Oncology;4
3;Copyright Page;5
4;Table of Contents;6
5;LIST OF CONTRIBUTORS;12
6;GENERAL PREFACE;14
7;PREFACE TO VOLUME II;16
8;Part I: Leukemias and Lymphomas;18
8.1;CHAPTER 1. THE ACUTE LEUKEMIAS;20
8.1.1;I. INTRODUCTION;20
8.1.2;II. INCIDENCE;21
8.1.3;III. CLASSIFICATION;21
8.1.4;IV. PREDISPOSING FACTORS;25
8.1.5;V. PRESENTING FEATURES;26
8.1.6;VI. DIFFERENTIAL DIAGNOSIS;27
8.1.7;VII. LABORATOvbRY FEATURES;28
8.1.8;VIII. GENERAL THERAPEUTIC CONSIDERATIONS;29
8.1.9;IX. GENERAL CLINICAL CONSIDERATIONS;31
8.1.10;X. PROGNOSTIC FACTORS;37
8.1.11;XI. CONCLUSIONS;39
8.1.12;ACKNOWLEDGMENTS;39
8.1.13;REFERENCES;39
8.2;CHAPTER 2. HAIRY CELL LEUKEMIA;42
8.2.1;I. DEFINITION;42
8.2.2;II. INCIDENCE WITH AGE AND SEX RATIO;42
8.2.3;III. PATHOLOGY;43
8.2.4;IV. PATHOGENESIS;43
8.2.5;V. CLINICAL FEATURES;45
8.2.6;VI. LABORAfgTORY FEATURES;46
8.2.7;VII. TREATMENT;50
8.2.8;VIII. COURSE OF DISEASE;52
8.2.9;IX. SUMMARY;52
8.2.10;REFERENCES;53
8.3;CHAPTER 3. CHRONIC LYMPHOCYTIC LEUKEMIA;56
8.3.1;I. DEFINITION;56
8.3.2;II. EPIDEMIOLOGY;57
8.3.3;III. ETIOLOGIC FEATURES;57
8.3.4;IV. PATHOLOGIC OBSERVATIONS;58
8.3.5;V. PATHOGENESIS;59
8.3.6;VI. CLINICAL FEATURES;61
8.3.7;VII. LABORATORY FEATURES;62
8.3.8;VIII. DIFFERENTIAL DIAGNOSIS;64
8.3.9;IX. TREATMENT;67
8.3.10;X. PROGNOSTIC FACTORS;68
8.3.11;XI. COURSE OF DISEASE;70
8.3.12;REFERENCES;71
8.4;CHAPTER 4. CHRONfghIC MYELOCYTIC LEUKEMIA;74
8.4.1;I. SPECIAL CHARACTERISTICS;74
8.4.2;II. CLINICAL FEATURES;76
8.4.3;III. CLINICAL COURSE;77
8.4.4;IV. SUMMARY AND CONCLUSIONS;84
8.4.5;ACKNOWLEDGMENTS;84
8.4.6;REFERENCES;85
8.5;CHAPTER 5. THE LYMPHOMAS;86
8.5.1;I. INTRODUCTION;86
8.5.2;II. HODGKIN'S DISEASE;88
8.5.3;III. NON-HODGKIN'S LYMPHOMAS;99
8.5.4;IV. CONCLUSION;111
8.5.5;ACKNOWLEDGMENT;111
8.5.6;REFERENCES;111
9;Part II: Solid Tumors;114
9.1;CHAPTER 6. CARCINOMA OF THE BREAST;116
9.1.1;I. INTRODUCTION;116
9.1.2;II. INCIDENCE AND CAUSATIVE FACTORS;117
9.1.3;III. PATHOLOGY;118
9.1.4;IV. CLINICAL PRESENTATION;119
9.1.5;V. PROGNOSTIC FEATURES;119
9.1.6;VI. CLINICAL COURSE OF METASTATIC BREAST CANCER;120
9.1.7;VII. SURGICAL THERAPY;121
9.1.8;VIII. RADIATION THERAPY;122
9.1.9;IX. HORMONAL THERAPY;123
9.1.10;X. CHEMOTHERAPY;123
9.1.11;XI. DISCUSSION;126
9.1.12;REFERENCES;127
9.2;CHAPTER 7. CLINICAL PRESENTATIONS OF GASTROINTESTINAL CANCER;130
9.2.1;I. LARGE-BOWEL CARCINOMA;130
9.2.2;II. CARCINOMA OF THE PANCREAS;134
9.2.3;III. CARCINOMA OF THE STOMACH;138
9.2.4;REFERENCES;140
9.3;CHAPTER 8. CANCERS OF THE HEAD AND NECK;142
9.3.1;I. INTRODUCTION;142
9.3.2;II. INCIDENCE;144
9.3.3;III. ETIOLOGY;144
9.3.4;IV. HISTOPATHOLOGY AND SPREAD;146
9.3.5;V. CLINICAL MANIFESTATIONS;147
9.3.6;VI. DIAGNOSIS;159
9.3.7;VII. CLINICAL STAGING;159
9.3.8;VIII. MANAGEMENT;160
9.3.9;IX. CONCLUSIONS;162
9.3.10;ACKNOWLEDGEMENT;163
9.3.11;REFERENCES;163
9.4;CHAPTER 9. CARCINOMA OF THE LUNG;164
9.4.1;I. INTRODUCTION;164
9.4.2;II. CLASSIFICATION;164
9.4.3;III. EVALUATION OF LUNG CANCER;167
9.4.4;IV. MANAGEMENT OF NON-SMALL CELL ANAPLASTIC CANCER;170
9.4.5;V. MANAGEMENT OF METASTATIC NON SMALL-CELL ANAPLASTIC LUNG CANCER;173
9.4.6;VI. EVALUATION AND MANAGEMENT OF SMALL-CELL ANAPLASTIC CARCINOMA;175
9.4.7;VII. CONCLUSION;180
9.4.8;REFERENCES;180
9.5;CHAPTER 10. CLINICAL CHARACTERISTICS OF CANCER IN THE BRAIN AND SPINAL CORD;184
9.5.1;I. INTRODUCTION;184
9.5.2;II. TUMORS OF THE BRAIN;185
9.5.3;III. MENINGEAL CARCINOMATOSIS;207
9.5.4;IV. TUMORS OF THE SPINAL CORD;209
9.5.5;ACKNOWLEDGMENTS;213
9.5.6;REFERENCES;214
9.6;CHAPTER 11. GENITOURINARY CANCER;216
9.6.1;I. INTRODUCTION;217
9.6.2;II. RENAL CARCINOMA;218
9.6.3;III. CARCINOMA OF THE RENAL PELVIS;223
9.6.4;IV. CARCINOMA OF THE URETER;227
9.6.5;V. FEMALE URETHRAL CARCINOMA;229
9.6.6;VI. MALE URETHxfdydRAL CARCINOMA;233
9.6.7;VII. PENILE CARCINOMA;235
9.6.8;VIII. TESTICULAR TUMORS;239
9.6.9;IX. BLADDER CANCER;248
9.6.10;X. PROSTATE CANCER;254
9.6.11;REFERENCES;258
9.7;CHAOPTER 12. GYNECOLOGICAL CANCERS;260
9.7.1;I. INTRODUCTION;260
9.7.2;II. OVARIAN CANCER;262
9.7.3;III. CANCER OF THE CERVIX;267
9.7.4;IV. ENDOMETRIAL CARCINOMA;271
9.7.5;ACKNOWLEDGMENT;272
9.7.6;REFERENCES;272
9.8;CHAPTER 13. MxfxALIGNANT MELANOMA;274
9.8.1;I. INTRODUCTION;274
9.8.2;II. EPIDEMIOLOGY;275
9.8.3;III. PATHOLOGY;276
9.8.4;IV. CLINICAL FINDINGS;284
9.8.5;V. DIAGNOSIS;287
9.8.6;VI. PROGNOSIS;288
9.8.7;VII. TREATMENT;289
9.8.8;VIII. CONCLUSION;291
9.8.9;REFERENCES;291
9.9;CHAPTER 14. THE SARCOMAS;294
9.9.1;I. INTRODUCTION;294
9.9.2;II. DIAGNOSIS;295
9.9.3;III. SOFT TISSUE SARCOMAS;296
9.9.4;IV. SARCOMAS OF BONE;303
9.9.5;V. CONCLUSION;309
9.9.6;REFERENCES;309
9.10;CHAPTER 15. PEDIATRIC CANCER;314
9.10.1;I. INTRODUCTION;314
9.10.2;II. TUMORS;315
9.10.3;III. CONCLUSIONS;334
10;Part III: Nutritional and Infectious Disease Aspects of Cancer;336
10.1;CHAPTER 16. INFECTIOUS COMPLICATIONS IN THE CANCER PATIENT;338
10.1.1;I. INTRODUCTION;338
10.1.2;II. TYPES OF INFECTION IN CANCER PATIENTS;347
10.1.3;III. DIAGNOSIS OF AND THERAPY FOR INFECTION;362
10.1.4;IV. THERAPY FOR NONBACTERIAL INFECTIONS;372
10.1.5;V. GRANULOCYTE TRANSFUSION;373
10.1.6;VI. PROPHYLAXIS OF INFECTION;375
10.1.7;VII. CONCLUSIONS;378
10.1.8;REFERENCES;378
10.2;CHAPTER 17. NUTRITION IN CANCER PATIENTS;382
10.2.1;I. INTRODUCTION;382
10.2.2;II. CANCER-MALNUTRITION ASSOCIATIONS;382
10.2.3;III. MECHANISMS OF CANCER-ASSOCIATED MALNUTRITION;383
10.2.4;IV. ADVANTAGES OF NUTRITIONAL SUPPORT;384
10.2.5;V. METHODS OF NUTRITIONAL SUPPORT;387
10.2.6;VI. CONCLUSION;388
10.2.7;REFERENCES;388
11;INDEX;390